Skip to content

A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Efficacy and Safety of Wireless Spinal Cord Stimulation (wSCS) in Chronic Pain Management

A Prospective, Multicenter, Randomized Controlled Trial Evaluating the Efficacy and Safety of Wireless Spinal Cord Stimulation (wSCS) in Chronic Pain Management

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097523
Enrollment
Unknown
Registered
2025-02-20
Start date
2025-03-03
Completion date
Unknown
Last updated
2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic pain of the trunk and/or limbs

Interventions

Experimental group:stimulation continued in the random period
Roll-in group:Stimulation continued in the random period

Sponsors

China-Japan Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Phase I Enrollment Criteria: 1. Participants aged 18 years or older. 2. Chronic intractable pain persisting for at least 3 months, refractory to conservative therapies (e.g., pharmacotherapy, physical therapy). 3. Baseline pain intensity >=5 on the Visual Analog Scale (VAS), documented in a 4-day pre-implantation diary. 4. Participants demonstrating good compliance and ability to complete postoperative follow-up. 5. Participants can understand the study procedures and sign the informed consent. Phase II Treatment Eligibility: Pain VAS scores during the test period show a =50% improvement compared to the baseline period.

Exclusion criteria

Exclusion criteria: 1. Spinal anatomical abnormalities prevented electrode implantation. 2. Pregnancy, breastfeeding, planned pregnancy, or refusal to use contraception. 3. Bleeding disorders or coagulation abnormalities. 4. Inability to cooperate during surgery or post-operative programming. 5. Life expectancy of less than one year. 6. Presence of implanted neurostimulators, cardiac pacemakers, or similar medical devices. 7. Participation in other clinical trials before reaching the primary endpoint. 8. Other conditions considered unsuitable by the investigators

Design outcomes

Primary

MeasureTime frame
The difference of maximal visual-analog scale (VAS) score between Experimental group and Conrol group in the withdrawal period compared with the baseline;

Secondary

MeasureTime frame
Changes in VAS Scores from Baseline;Response Rate (= 50% reduction VAS);Achievement Rate of a Desirable Pain State (VAS score <=3);Pittsburgh Sleep Quality Index (PSQI);Beck Depression Inventory (BDI);Health-Related Quality of Life Questionnaire (SF-36);The Use of Medications Related to Pain Management;Device Comfort Assessment (7-Point Likert Scale);Device Usability Evaluation (7-Point Likert Scale);Device Operability Assessment (7-Point Likert Scale);Surgical Success Rate;Surgical Duration;Intraoperative Blood Loss;

Countries

China

Contacts

Public ContactFan Bifa

China-Japan Friendship Hospital

fbf1616@yeah.net+86 150 1010 1616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026